[{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tenalisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Curon Biopharmaceutical","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Curon Biopharmaceutical \/ Curon Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Curon Biopharmaceutical \/ Curon Biopharmaceutical"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by Curon Biopharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : $700.0 million

                          September 08, 2024

                          Lead Product(s) : CN201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : $1,300.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the terms of the agreement, Merck through a subsidiary acquired full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : $700.0 million

                          January 10, 2024

                          Lead Product(s) : CN201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : $1,300.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 31, 2021

                          Lead Product(s) : CN202

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Novotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 10, 2021

                          Lead Product(s) : CN1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Novotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 10, 2020

                          Lead Product(s) : Tenalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Rhizen Pharmaceuticals

                          Deal Size : $149.5 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 05, 2020

                          Lead Product(s) : CN1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Novotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank